Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sumatriptan Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

NCT00875784
View directory record Official record
Conditions
Migraine Disorders
Interventions
TREXIMA™, IMITREX® (4mg), IMITREX® (6mg), IMITREX Tablet 100mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 18, 2026, 2:45 PM EDT
Withdrawn Not applicable Interventional

Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department

NCT00573599
View directory record Official record
Conditions
Acute Migraine Headache
Interventions
prochlorperazine and benadryl IV, Imitrex SubQ, saline IV
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

NCT00546650
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan succinate
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 18, 2026, 2:45 PM EDT
Terminated Phase 4 Interventional Results available

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT01053507
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
sumatriptan/naproxen sodium, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Springfield, Missouri • Nashville, Tennessee • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 4 Interventional

Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex

NCT01450995
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Imitrex and two Aleve
Drug
Lead sponsor
Stephen H. Landy, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.

NCT00989625
View directory record Official record
Conditions
Migraine Disorders
Interventions
This is a pharmacokinetic study (Treximet)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Wichita, Kansas • Louisville, Kentucky • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

NCT00846885
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan Succinate, Imitrex®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 40 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

NCT03310411
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Sumatriptan, Placebo for Lasmiditan, Placebo for Sumatriptan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches

NCT00434083
View directory record Official record
Conditions
Migraine Headaches
Interventions
sumatriptan, naproxen sodium
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2007 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine

NCT01807234
View directory record Official record
Conditions
Migraines
Interventions
Ketorolac, Sumatriptan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

NCT01430442
View directory record Official record
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240630
View directory record Official record
Conditions
Migraine Disorders, Migraine
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
50
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 18, 2026, 2:45 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study in Participants With Acute Migraines Headaches

NCT00804973
View directory record Official record
Conditions
Migraine Headache
Interventions
LY2590443, Placebo injection, Sumatriptan, Placebo capsule
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
19
States / cities
Beverly Hills, California • Chula Vista, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treximet Early Intervention Adolescent Migraine

NCT01016678
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Premiere Research Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

NCT00806546
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 3 Interventional

Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

NCT00329355
View directory record Official record
Conditions
Migraine, Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
35
States / cities
Chandler, Arizona • Irvine, California • Redondo Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 18, 2026, 2:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache

NCT01916395
View directory record Official record
Conditions
Migraine
Interventions
sumatriptan and Treximet
Drug
Lead sponsor
Gary E. Ruoff, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine

NCT01300546
View directory record Official record
Conditions
Migraine
Interventions
Sumatriptan/Naproxen Sodium, Naproxen Sodium
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Newport Beach, California • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

NCT03076970
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg, Sumatriptan, matching placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

NCT01381796
View directory record Official record
Conditions
Compare Bioequivalence Patches Previously Used in the NP101-007 Study
Interventions
NP101, sumatriptan succinate
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

NCT04355845
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Sumatriptan, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 18, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

NCT00723983
View directory record Official record
Conditions
Migraine Disorders
Interventions
Sumatriptan succinate, NP101 Study Patch
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 18, 2026, 2:45 PM EDT